PharmEasy is an Indian healthcare platform that offers online diagnostic tests, medicines, and consultations with doctors. The company was founded on 26 November 2014 by Dhaval Shah and Dharmil Sheth in Mumbai, with funding provided by API Holdings LTD’s parent organisation. It is a private company with industry types in healthcare, eCommerce, informational, and technological retail. PharmEasy, just a few months back, was one of India’s most sought-after digital pharmacy portals. However, a lot has changed for the PharmEasy unlisted share price in the last few months. The latest financial reports of PharmEasy brought a piece of bad news for the company, where its digital ecosystem proved to be damaged.

 

Let’s look into the reason for the downfall of PharmEasy stock price and how the company plans to fight back and take back control over the Pharmacy share price. Check PharmEasy share price at Stockify!

 

Jolts In The PharmEasy Unlisted Share Price

The leading national online healthcare services and drug provider, PharmEasy, has been the topic of talks due to the widening losses to Rs 2,700 crore. The company is contacting its investors to raise a capital of $200 million, though at a stark valuation that could be 15% to 25% lower than the last year’s valuation of $5.1 billion. 

 

The Indian startups faced a significant shock in their stock prices due to inevitable reasons, uncertain global and domestic stock markets being major ones of them. The PharmEasy IPO also underwent rising inventors’ scepticism over what they called a “sky-high valuation”. It was one of the prominent reasons why Phrameasy company was having difficulty raising funds at the same or higher valuation. It is said that PharmEasy unlisted shares are backed by big-name investors such as TPG, Prosus and Temasek. The company is in talks to secure new funds at a valuation of 15% lower than that of last year.

 

There are also theories circulating regarding the loss of PhramEsay shares that the company has contacted its bankers to consider a 25% reduction in medicine deliveries and diagnostic test services. This could bring down PharmEasy valuation for the new funding by close to $3.8 billion. The total expenses for the fiscal year to March 2022 amounted to $1.06 billion, partially because of one-time employee stocks benefit outlay (based on a document viewed by Reuters that listed PharmEasy’s latest unaudited financials).

 

According to Reuter’s document, the net loss of the PharmEasy unlisted share price for the year 2022 quadrupled to $334 million.